Harry A. Drabkin, M.D.

Accepting New Patients

Accepting New Patients

Provider Image

New Patients

843-792-9300 843-792-9300

29 day(s) until next new
patient appointment as of
8:30 a.m. .

What is this?


If the time frame shown for a new patient appointment for this provider is not convenient, please call 843-792-9300 for an appointment with one of their colleagues.

Returning Patients

Title
  • Professor
  • Mary Gilbreth Chair in Clinical Oncology
Degree M.D.
School University of Kansas School of Medicine
Residency
  • University of Cincinnati
Fellowship
  • University of Colorado Health Sciences Center
Board Certification
  • Internal Medicine
  • Internal Medicine: Medical Oncology
Specialties
  • Hematology/Oncology
  • Cancer - Prostate & Genitourinary
Accepts New Patients Yes

New Patients

843-792-9300 843-792-9300

29 day(s) until next new
patient appointment as of
8:30 a.m. 3/25/2017.

What is this?


If the time frame shown for a new patient appointment for this provider is not convenient, please call 843-792-9300 for an appointment with one of their colleagues.
To request an appointment call our representatives at 843-792-1414

Returning Patients

Locations

Hollings Cancer Center
86 Jonathan Lucas Street
Charleston, SC 29425
Map & Directions
 

Biography

Dr. Harry Drabkin is professor of medicine, Gilbreth chair in clinical oncology at the Medical University of South Carolina. He received his M.D. degree from the University of Kansas, completed his internship and residency in internal medicine at the University of Cincinnati, and was a fellow in hematology-oncology at the University of Colorado. While at Colorado, Dr. Drabkin rose through the ranks to become full professor in 1998 and received the Grohne-Stapp chair in cancer research in 2006. Dr. Drabkin joined MUSC in May 2007.

Dr. Drabkin has made major contributions to our understanding of the pathogenesis of leukemia, kidney cancer and lung cancer. Among his accomplishments are the discovery of the AML1-ETO fusion transcript from the 8;21 translocation in AML, the discovery and function of the hereditary kidney cancer gene, TRC8, and the identification of the tumor suppressor gene, SEMA3F and its role and regulation in lung cancer. Clinically, Dr. Drabkin is recognized in the treatment of metastatic kidney cancer and is active in cooperative group, industry, and investigator-initiated clinical trials for this disease. He is the author of more than 160 peer-reviewed articles and book chapters.